In this article, we will look at the 5 Stocks With Eye-Popping Gains. For a deeper discussion and an extended list, please see 10 Stocks With Eye-Popping Gains.

5. Almonty Industries Inc. (NASDAQ:ALM)

Almonty Industries extended gains for a second day on Monday, soaring 15.32 percent to close at $20.62 apiece, as investors took heart from its support for the US government’s critical minerals expansion with its relocation to the US.

In a statement, Almonty Industries Inc. (NASDAQ:ALM) said that its headquarters is set to move to Dillon, Montana, from Toronto, Ontario, reflecting its continued strategic alignment with the United States and its role in supporting secure, transparent, and Western-aligned supply chains for critical materials.

The move was in line with its ambitious goal of becoming a leading tungsten producer in the US, and followed its acquisition of the Gentung Tungsten Project in Montana. Production at the mine site is expected to restart this year.

“Relocating our headquarters to the United States is not merely symbolic. It reflects who we are—as Montana is the location of our recently acquired Gentung Tungsten Project—and where our future lies. Our investors, customers, and strategic partners are here because they recognize the urgency of building a Western tungsten supply chain free from Chinese dependence,” Almonty Industries Inc. (NASDAQ:ALM) Chairman, President, and CEO Lewis Black said.

“With Sangdong Phase 1 complete and Gentung on track to begin production, we are delivering on that mission, and a US home base ensures we remain at the center of it,” he noted.

4. Sigma Lithium Corp. (NASDAQ:SGML)

Sigma Lithium climbed to a new two-year high on Monday, as investors loaded portfolios amid rosy prospects from the continued surge in demand for electric vehicles.

In intra-day trading, the stock climbed to its highest price of $17.58 before paring gains to finish the session just up by 17.10 percent at $17.39 apiece.

Since the start of the US and Israel’s war on Iran, online marketplaces have seen a surge in interest in electric vehicles, with buyers said to be on the lookout for other alternatives to mitigate risks from the spiking global crude oil prices.

Mobile.de, the largest vehicle marketplace in Germany, said the new and used car marketplace had seen an over 50 percent jump in EV inquiries in March compared to February.

Meanwhile, Carwow reported a 20 to 30 percent jump in EV inquiries in the UK, Spain, and Germany between February and March, with demand in the UK alone up 23 percent last month versus February.

The development spelled good news for Sigma Lithium Corp. (NASDAQ:SGML)—a Brazil-based maker of high-purity lithium concentrate for EVs—as more EV sales translate to stronger demand for its products.

In other news, Sigma Lithium Corp. (NASDAQ:SGML) earlier this month successfully raised $100 million in fresh funds from a collateralized bank guarantee.

The lithium maker said proceeds from the loan would support the construction and installation of its Greentech Industrial Plant 2, in line with goals to upsize its nameplate capacity to 520,000 tons from 270,000 tons.

Sigma Lithium Corp. (NASDAQ:SGML) said the guarantee will be collateralized by its clients through a blend of corporate guarantees, letters of credit, and export receivables to be mutually agreed upon amongst the parties.

3. Spyre Therapeutics Inc. (NASDAQ:SYRE)

Spyre Therapeutics soared to a new four-year high on Monday, as investors took heart from the best-in-class potential of its treatment for ulcerative colitis (UC) and the stock’s 40-percent price target upgrade from an investment firm.

In intra-day trading, the stock climbed by as much as 46 percent to a high of $75, before trimming gains to finish the session just up by 23.36 percent at $63.27 apiece.

In an updated report, Spyre Therapeutics Inc. (NASDAQ:SYRE) said that its treatment candidate, SPY001, saw a clinical remission rate of 40 percent at 12 weeks versus Entyvio’s 27 percent at 14 weeks.

The drug also demonstrated an improvement of 51 percent in endoscopic versus its competitor’s 41 percent at six weeks.

Following the news, BTIG upgraded its price target for Spyre Therapeutics Inc. (NASDAQ:SYRE) to $98 from $70 previously, while maintaining its “buy” recommendation.

BTIG raised to 80 percent its expectations for SPY001 combinations to succeed, as well as penetration rates for UC and Crohn’s disease to 30 and 20 percent, respectively.

In other news, Spyre Therapeutics Inc. (NASDAQ:SYRE) kicked off a $300 million share sale in line with plans to raise funds to support its pipeline programs.

It also granted its underwriters a $45 million overallotment option at the same price for 30 days from the public offering date.

2. Avis Budget Group Inc. (NASDAQ:CAR)

Avis Budget extended its rally for a 9th straight session on Monday, to hit an all-time high, as short traders continued to gobble up its stock amid uncertainties in the Middle East.

In intra-day trading, Avis Budget Group Inc. (NASDAQ:CAR) jumped to its highest price of $372.23 before paring gains to finish the day just up by 23.69 percent at $371.01 apiece.

The rally can be attributed to the uncertainties in the ongoing peace talks between the US and Iran, whose war over the past few weeks has sent global crude oil prices spiking.

This, on the other hand, sparked good news for used car and car rental stocks like Avis Budget Group Inc. (NASDAQ:CAR) and Hetz Global Holdings, as travelers look for alternative modes of transportation to mitigate risks from the oil spikes and uncertainties.

Additionally, Avis Budget Group Inc. (NASDAQ:CAR) is a heavily shorted company, with at least 20 percent of its total float sold short, giving room for potential breakout rallies.

Last year, the company narrowed its net loss by 51 percent to $889 million from $1.82 billion in 2024. Revenues decreased by 1.6 percent to $11.6 billion from $11.79 billion year-on-year.

In the fourth quarter alone, Avis Budget Group Inc. (NASDAQ:CAR) incurred an attributable net loss of $747 million, or 61.8 percent lower than the $1.958 billion year-on-year. Revenues dipped 1.7 percent to $2.66 billion from $2.7 billion year-on-year.

1. Revolution Medicines Inc. (NASDAQ:RVMD)

Revolution Medicines soared to a fresh all-time high on Monday, as investors cheered the stellar results from the clinical trial of its pancreatic cancer treatment, daraxonrasib.

In an updated report, Revolution Medicines Inc. (NASDAQ:RVMD) said that Daraxonrasib recorded a median overall survival of 13.2 months versus only 6.7 months for chemotherapy.

“Daraxonrasib as a targeted medicine delivered a dramatic improvement in overall survival in patients with previously treated metastatic pancreatic cancer compared to standard of care chemotherapy, consistent with earlier findings. These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape,” Revolution Medicines Inc. (NASDAQ:RVMD) Chairman and CEO Mark Goldsmith said.

“We are moving with urgency toward global regulatory submissions and remain committed to rapidly advancing this therapy for patients with a broad range of RAS-addicted cancers,” he noted.

Revolution Medicines Inc. (NASDAQ:RVMD) said it is planning to submit the overall data to regulators, including the Food and Drug Administration (FDA), as part of its future New Drug Application.

Following the news, investment firm Raymond James issued a “strong buy” recommendation for Revolution Medicines Inc.’s (NASDAQ:RVMD) stock, alongside a price target of $175, marking a 30 percent upgrade from $135 previously.

Meanwhile, Bank of America gave a $170 price target, or a 48 percent upgrade from $115, while maintaining a “buy” recommendation.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.